Genetics of Pancreatic Cancer and Its Implications on Therapy

被引：13

作者：

Tatarian, Talar ^{[1
]}

Winter, Jordan M. ^{[2
]}

机构：

[1] Thomas Jefferson Univ Hosp, Dept Surg, Jefferson Pancreas Biliary & Related Canc Ctr, Sidney Kimmel Med Coll, 1015 Walnut St,Suite 620, Philadelphia, PA 19107 USA

[2] Thomas Jefferson Univ Hosp, Dept Surg, Jefferson Pancreas Biliary & Related Canc Ctr, Sidney Kimmel Med Coll, 1025 Walnut St,Suite 605, Philadelphia, PA 19107 USA

来源：

SURGICAL CLINICS OF NORTH AMERICA | 2016年 / 96卷 / 06期

关键词：

Pancreatic cancer; Genetics; Personalized medicine; Targeted therapy; PHASE-II TRIAL; GROWTH-FACTOR RECEPTOR; DUCTAL ADENOCARCINOMA; 1ST-LINE TREATMENT; PLUS GEMCITABINE; OPEN-LABEL; K-RAS; MUTATIONS; TRASTUZUMAB; KRAS;

D O I：

10.1016/j.suc.2016.07.014

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Over the past decade, emerging technologies have provided new insights into the genomic landscape of pancreatic ductal adenocarcinoma (PDA). In addition to the commonly recognized genetic drivers of pancreatic carcinogenesis (KRAS, CDKN2A, TP53, SMAD4), new genes and pathways have been implicated. However, these efforts have not identified any new high-frequency actionable mutations, limiting the success of mutation-targeted therapy in PDA. This article provides a report on the current landscape of pancreas cancer genetics and targeted therapeutics.

引用

页码：1207 / +

页数：16

共 50 条

[41] The genetics of nicotine dependence:Relationship to Pancreatic cancer
Stewart L MacLeod
Parimal Chowdhury
World Journal of Gastroenterology, 2006, (46) : 7433 - 7439
[42] Emerging drugs in the treatment of pancreatic cancer
Mahalingam, Devalingam
Kelly, Kevin R.
Swords, Ronan T.
Carew, Jennifer
Nawrocki, Steffan T.
Giles, Francis J.
EXPERT OPINION ON EMERGING DRUGS, 2009, 14 (02) : 311 - 328
[43] Oncogenic KRAS signalling in pancreatic cancer
Eser, S.
Schnieke, A.
Schneider, G.
Saur, D.
BRITISH JOURNAL OF CANCER, 2014, 111 (05) : 817 - 822
[44] Mucins in pancreatic cancer: biological role, implications in carcinogenesis and applications in diagnosis and therapy
Suh, Hyerim
Pillai, Krishna
Morris, David Lawson
AMERICAN JOURNAL OF CANCER RESEARCH, 2017, 7 (06): : 1372 - 1383
[45] Pancreatic cancer: Translational research aspects and clinical implications
Ansari, Daniel
Chen, Bi-Cheng
Dong, Lei
Zhou, Meng-Tao
Andersson, Roland
WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (13) : 1417 - 1424
[46] Advances in Targeted Therapy and Immunotherapy for Pancreatic Cancer
Liu, Xiaoxiao
Li, Zhang
Wang, Yuexiang
ADVANCED BIOLOGY, 2021, 5 (03):
[47] Clinical Significance of the Genetic Landscape of Pancreatic Cancer and Implications for Identification of Potential Longterm Survivors
Yachida, Shinichi
White, Catherine M.
Naito, Yoshiki
Zhong, Yi
Brosnan, Jacqueline A.
Macgregor-Das, Anne M.
Morgan, Richard A.
Saunders, Tyler
Laheru, Daniel A.
Herman, Joseph M.
Hruban, Ralph H.
Klein, Alison P.
Jones, Sian
Velculescu, Victor
Wolfgang, Christopher L.
Iacobuzio-Donahue, Christine A.
CLINICAL CANCER RESEARCH, 2012, 18 (22) : 6339 - 6347
[48] Signalling in pancreatic cancer: from pathways to therapy
Zhou, Kexun
Liu, Yingping
Yuan, Shiman
Zhou, Ziyu
Ji, Pengfei
Huang, Qianhan
Wen, Feng
Li, Qiu
JOURNAL OF DRUG TARGETING, 2023, 31 (10) : 1013 - 1026
[49] Neoadjuvant Therapy of Pancreatic Cancer: The Emerging Paradigm?
Lim, Kian-Huat
Chung, Eugene
Khan, Adeel
Cao, Dengfeng
Linehan, David
Ben-Josef, Edgar
Wang-Gillam, Andrea
ONCOLOGIST, 2012, 17 (02) : 192 - 200
[50] Evolution of systemic therapy for advanced pancreatic cancer
Renouf, Daniel
Moore, Malcolm
EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (04) : 529 - 540

← 1 2 3 4 5 →